objectives Meglumine antimoniate (MA; Glucantimeâ), the 80-year-old first-line systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by Leishmania (Viannia) braziliensis, Leishmania (Viannia) guyanensis and Leishmania (Leishmania) amazonensis, is highly toxic, presents adverse side-effects and may not attain clinical and parasitological cure. This critical review examines the necessity for intramuscular/intravenous administration of MA, the alternatives to this approach, and the possibilities of developing affordable, accessible and non-toxic drugs or new delivery methods.
Introduction
American tegumentary leishmaniasis (ATL) is a povertyrelated neglected tropical disease (NTD) that produces hard-to-heal skin sores, leaves gruesome scars and can spread from the skin to the mucous membranes of the nose, mouth and throat [1] . At least seven species of Leishmania (Trypanosomatidae) are responsible for human ATL in Brazil with the main agents being, by order of prevalence, Leishmania (Viannia) braziliensis, Leishmania (Leishmania) amazonensis and Leishmania (Viannia) guyanensis [2, 3] .
During the early 1900s, ATL was treated using trivalent antimony Sb(III) salts, more specifically antimony potassium tartrate or emetic tartar, but administration of these compounds was discontinued following the development of less toxic Sb(V)-based drugs. Examples of Sb (V) agents are sodium antimony(V) gluconate (syn. sodium stibogluconate), which is available in the United States, Europe and China, and meglumine antimoniate (MA) (syn. N-methyl glucamine: NMG), which is the drug of choice in Africa and Latin America [4, 5] . Both Sb(V) agents have similar mechanisms of action, pharmacokinetics and efficacies.
Meglumine antimoniate has been available in Brazil since the 1940s, and remains the only Sb(V) drug authorised by the Brazilian Ministry of Health for use in firstor second-line treatment against all forms of ATL [6] . Currently, MA is commercialised in Brazil exclusively by Sanofi-Aventis Farmacêutica Ltda (Suzano, SP, Brazil) [7] under the trade name Glucantimeâ and is available throughout the Brazilian National Health Service (Sistema Unico de Saude -SUS) [8] . Although no generic versions of MA are presently available, research groups in Brazil have been working on new processes for the production of a generic drug [9, 10] .
Meglumine antimoniate is presented commercially in the form of an aqueous solution comprising a mixture of 2:3 and 3:3 complexes [11] with the structural formula shown in Figure 1 [12] . The degree of polymerisation may vary from batch to batch and with time of storage, such that Sb(V) bioavailability, safety and efficacy of the drug may be subject to change [13] . Glucantime is supplied in 5 ml ampoules containing 300 mg/ml of MA, which is theoretically equivalent to a concentration of active principle Sb(V) of 81 mg/ml and a total Sb(V) dose of 405 mg per ampoule. The prescribed dose must be based on the amount of Sb(V) present, but discrepancies between the total concentrations of MA and Sb(V) in the ampoules may lead to prescription errors. The standard therapeutic regimen for adults and children depends on the form of ATL and ranges from 10 to 20 mg Sb(V)/kg/ day administered over 20-30 consecutive days via an intravenous (IV) or intramuscular (IM) route, with treatment repeated if necessary. However, the elderly, pregnant women, patients with comorbidities or other coinfections, such as human immunodeficiency virus and different pathogens, may require special interventions [6] . The form of administration of MA represents a major drawback since it is distressing to most patients, particularly children, causes pain, local reactions and a variety of other adverse effects in a significant proportion of patients, factors that are likely responsible for the high level of non-adherence to treatment.
It is notable that some NTDs are more neglected than others, and this would certainly appear to be the case for ATL in Brazil since treatment relies almost exclusively on a drug that has been around for 80 years, exhibits high toxicity with adverse and potentially fatal effects and may not attain clinical and parasitological cure. In the light of the above considerations, we raised the following questions: (i) is the systemic treatment of ATL with MA really necessary? (ii) are there alternatives to this approach in the form of new delivery methods for MA? and (iii) what are the possibilities of developing affordable, accessible and non-toxic drugs with delivery methods that are more patient-friendly? This review aims to answer these questions by presenting an overview of the mode of action, pharmacokinetics, efficacy and toxicity of MA, by evaluating the progress of ATL therapy in Figure 1 Chemical structure of meglumine antimoniate in commercial Glucantime as proposed by Fr ezard et al. [12] .
Brazil and by assessing the feasibility of drug repositioning or nanotechnology for accelerating the identification and/or optimisation of a substitute medicine. Given that pharmaceutical industries have little interest in NTDs from a commercial point of view, we hope to draw attention to the need of focusing academic research on the antileishmanial activity of known medicines and/or novel delivery methods that could be applied in the treatment of ATL [14] .
Methods
Relevant literature was identified by searching the PubMed and MEDLINE databases. Searches aimed to identify titles containing the terms 'cutaneous leishmaniasis' OR 'American tegumentary leishmaniasis' AND 'meglumine antimoniate' OR 'N-methyl glucamine' OR 'drug repositioning' OR 'nanotechnology' OR 'glucantime' OR 'miltefosine' OR 'novel'. Criteria for the selection of articles were relevance to the topics of the review and most up-to-date publications covering a period of 20 years of peer reviewed journals and technical bulletins. The initial number of records identified was 1121 but after screening the titles, 848 were excluded due to duplication of records and lack of relevancy. Abstracts of the 273 remaining articles were analysed carefully and 115 full papers were considered to be eligible for complete analysis and subsequent data extraction.
Overview of meglumine antimoniate
Mode of action and pharmacokinetics. There is evidence that the antileishmanial activity of MA is due to direct and indirect mechanisms. The direct effects are associated with interactions between the drug and biomolecules within the parasite, and two main models have been proposed for the mechanism. The Sb(V)-active model assumes that Sb(V) exhibits inherent antileishmanial activity through the formation of complexes with ribonucleosides, thereby disrupting the function of topoisomerases that are essential for DNA replication and transcription [13] .
The alternative pro-drug model postulates that Sb(V) is reduced to the more active Sb(III) within Leishmania amastigotes via a redox system involving trypanothione, a spermidine-glutathione conjugate that is unique to the kinetoplastid protozoa. There is additional evidence that parasite-specific enzymes, such as the thiol-dependent reductase TDR1 [15] and/or antimoniate reductase LmACR2 [16] , take part in this reduction process. The Sb(III) so-formed interacts with sulphydryl-containing biomolecules of the parasite, including peptides, proteins and enzymes, leading to a cascade of oxidative stressinducing events and culminating with DNA fragmentation and programmed cell death (apoptosis) [13] . Evidence in support of this model includes the finding that Sb(III) inhibits the trypanothione reductase system that is vital for parasite survival and virulence [17] . However, Sb(V) may also be reduced in vivo to Sb(III) by glutathione, cysteine or cysteinyl-glycine systems that operate within the compartments of mammalian cells.
Indirect mechanisms of action of MA are associated with the modulation of host responses. There is evidence that the drug increases the levels of circulating proinflammatory cytokines, such as interleukin-1b (IL-1b), IL-6, IL-8 and tumour necrosis factor alpha (TNF-a) [18] , and enhances the phagocytic activities of monocytes and neutrophils, which constitute the first-line of defence against the parasite, as well as the production of superoxide anions by these cells [19] .
The effectiveness of any drug depends on its bioavailability, which in turn is affected by the route of administration, typically, oral, IV or IM, each of which have advantages and disadvantages. The bioavailability of drugs administered orally varies considerably because it depends on the pKa of the drug and the changes in pH that occur during passage through the gastrointestinal (GI) tract. The oral route is efficient for drugs that can be easily absorbed and that do not produce inflammatory reactions in the gut. The IV route circumvents the absorption barriers of the gut and is the most effective way of delivering aqueous solutions of drugs to the systemic circulation with bioavailability reaching 100%. Indeed, the IV route is the best method of achieving a therapeutically effective drug concentration and controlling the duration of the effect. The bioavailability of drugs administered via the IM route is also high and depends mainly on muscle blood flow, although the effectiveness of the drug can be improved by altering the vehicle [20] .
The pharmacokinetics of Sb(V) administered by a parenteral route may be described by considering a twocompartment model comprising blood and well perfused organs such as liver and kidney as the main compartments, and poorly perfused tissues such as muscle, lean tissue and fat as peripheral compartments. The three pharmacokinetic phases consist of: (i) an initial rapid absorption phase (for IM injection) with a half-life ranging between 0.36 and 0.85 h and peak plasma concentration occurring between 0.5 and 2 h; (ii) a short elimination phase with a mean half-life of 2 h and (iii) a slow elimination phase with a mean half-life of 24-76 h (for both IM and IV injection). The slow elimination phase may be associated with the conversion of Sb(V) to Sb(III), which could contribute to the toxicity associated with long-term and high-dose therapy. Nonetheless, renal clearance is the main route of excretion for MA, with most of the Sb being eliminated within 24 h [21] . Drug exposure is lower in children than in adults treated with the same weight-adjusted regimen of MA because of the higher Sb clearance rate [22] , and for this reason a continuous high-dose therapy is necessary to maintain satisfactory tissue levels [23] .
The highest accumulation of Sb occurs in liver tissue, followed by the thyroid and heart. Distribution to the skin is slightly delayed in comparison with whole blood, with maximum concentrations being attained after 2.1 and 1.5 h respectively. No differences in Sb distribution between healthy and cutaneous lesions have been recorded. Nevertheless, the concentrations of Sb in the skin of ATL patients measured after 20 days of conventional therapy with doses of 10-20 mg Sb(V)/kg/day, showed high variability (range 7.46-70.68 lg/g), indicating that Sb concentrations in this tissue could affect the efficacy of the treatment [21] . Accumulation of Sb has also been reported in the hair of patients even 1-year after the termination of treatment with MA [24] .
In contrast, the distribution, accumulation and metabolism of Sb at the intracellular level have yet to be investigated in detail. Such information would be of particular importance since Leishmania promastigotes are initially internalised by phagolysosomes, where they subsequently proliferate and develop into amastigotes that are eventually released into the extracellular fluid as amastigotes or even as promastigote-like forms [25] . It is evident, therefore, that Sb must cross cell membranes in order to target the parasite during its reproductive phase. Insights into the intracellular pharmacokinetics of Sb in Leishmaniainfected macrophages have been provided by G omez et al. [26] However, the mechanism of Sb(V) uptake by macrophages is still unknown.
Efficacy and side effects
Drug-related factors, such as manufacturing process, composition, purity and stability of product, mode of administration and length of treatment, are partially responsible for the efficacy of MA therapy and the associated side effects. Other factors that affect the efficacy of therapy are those related to the host, for example age, gender, weight, bacterial and viral coinfections, comorbidities, duration, number, localisation and duration of lesions, drug metabolism and compliance with treatment, and those pertaining to the parasite, namely virulence and pathogenicity, including the presence of endogenous Leishmania RNA virus 1 (LRV1) in the circulating Leishmania species [27] . Although skin sores caused by Leishmania infection often remain localised and may even be self-healing, patients infected with L. (V.) braziliensis, L. (V.) guyanensis or Leishmania (Viannia) panamensis are at risk of developing mucocutaneous ATL, whereas those infected with L. (L.) amazonensis may develop the disseminated or diffuse forms of ATL that are characterised by secondary ulcers. Lesions resulting from metastatic leishmaniasis are generally associated with severe inflammation accompanied by bacterial or fungal infection, are poorly responsive to conventional therapies and may appear a long time after the initial ulcers have healed.
The criteria of cure are based on clinical parameters and defined as re-epithelialisation, disappearance of crusts, flattening of the borders of the lesions, absence of new lesions and reduction in erythema within 3 months of treatment, along with confirmation of healing of the mucosal lesions within 6 months following the termination of treatment. However, there are numerous reports describing therapy failure and reactivation of the disease after clinical cure, especially in patients with mucocutaneous [4, 28] and the disseminated/diffuse forms of ATL that are poorly responsive or unresponsive to treatment and associated with frequent relapses [29] . This phenomenon is due to parasite evasion from the host immune system and, consequently, persistence of the amastigotes in skin and mucosal tissues. For these reasons, cure criteria should also include parasitological and therapeutic parameters [27] .
Owing to the multifactorial nature of ATL it is not surprising that rates of treatment failure vary in different regions with, for example values of 7%, 39% and 16% having being quoted for Bolivia, Colombia and Brazil respectively [3] . Moreover, the risk of therapeutic failure is higher in children compared with adults [30] . Indeed, the clinical cure rates for patients treated by systemic administration of MA with standard doses of 20 mg Sb/ kg/day have been variously reported as 55.5% for patients infected with L. (V.) guyanensis [31] , 62% and 90% for patients infected with L. (V.) braziliensis [32, 33] and 85.1% for patients infected with L. (V.) braziliensis or L. (V.) panamensis [34] .
The adverse effects of MA are numerous and range from general mild complaints to serious complications that can lead to death. A systematic review of the secondary effects of ATL treatment in the Americas has been published by Oliveira et al. [35] . Among the clinical adverse effects most frequently reported are myalgia, arthralgia, gastrointestinal disturbances (nausea, vomiting, diarrhoea, abdominal pain), headache, anorexia, asthenia, fatigue, fever and cutaneous reactions (exanthema, erythema and urticaria). However, cardiovascular alterations, which comprise ventricular repolarisation alterations such as T-wave inversion/flattening and prolongation of the QTc interval, are the most serious and, being both dose-and time-dependent, require constant monitoring during IV or IM administration of the drug. The most frequent laboratory-detected alterations are associated with liver and pancreatic functions and generally involve increases in levels of alanine transaminase, aspartate transaminase, lipase and amylase [35] . Often treatment has to be interrupted because of such dysfunctions and, when necessary, second-line drugs (conventional/liposomal amphotericin B and pentamidine) are used, but these are equally toxic and systemically delivered [6] .
Although the IV/IM formulation of the drug is reasonably effective with clinical cure rates typically in the range 60-90%, the treatment should not be worse than the disease itself, which appears to be the case at present. However, this scenario finally began to change a little in 2014 following publication of updated guidelines for the treatment of leishmaniasis in the Americas by the Pan American Health Organisation [36] . Moreover, a phase III randomised controlled, non-inferiority, blind trial conducted in Rio de Janeiro between 2008 and 2014 [37] revealed that a clinical cure rate of 77.8% of subjects could be achieved with a low dosage (5 mg Sb(V)/kg/day) of MA. Although therapy with conventional levels of the drug (20 up to 1215 mg Sb(V)/kg/day) produced a higher clinical cure (94.4%), such treatment was accompanied by significantly greater numbers of adverse events and more drug-related discontinuations. Similar therapeutic responses to low doses of MA have been reported for patients who acquired ATL in different regions of Brazil [38] .
An alternative treatment that could reduce the side effects of the systemic absorption of MA involves subcutaneous injection of the drug directly into the lesions. The technique has been applied in Brazil to a limited extent for more than two decades, but the evidence base for the efficacy of the treatment has been somewhat deficient. Following a systematic review of the outcomes of intralesional infiltration with Sb(V) in the treatment of cutaneous leishmaniasis worldwide, Brito et al. [39] reported that the overall cure rate was around 75%, a value similar to that obtained by parenteral administration of antimonials. However, the authors point out the necessity to ascertain the causative Leishmania species prior to the commencement of treatment and to employ a standardised intralesional technique. Silva et al. [40] have recently developed and validated a standard operational procedure (SOP) for intralesional infiltration of MA, and the technique was subsequently employed in a phase II, single arm, open label clinical trial to assess its safety and effectiveness [41] . According to these authors, a cure rate of 87% was achieved using the SOP and the majority of adverse events recorded were local and of mild or moderate intensity.
In 2017, the Brazilian Ministry of Health adapted the existing ATL management protocols to Brazilian reality [6] , taking into consideration the forms of the disease, the circulating Leishmania species and the availability of medications in the various levels of health care (Figure 2) . At this point, we can answer the first two questions about whether the parenteral administration of MA is really necessary and if there are alternatives to this approach. The response is affirmative, that is the continuity of the systemic regimen is still the most effective and affordable first-line treatment for all forms of ATL, except the cuta- ) guyanensis developing mucocutaneous ATL is negligible so that the lesions can be treated in loco instead of using systemic therapy. Hence, the single most important advancement in the first-line therapy of ATL with MA to have emerged over the last decades is the intralesional application of the drug. Subcutaneous application using an SOP facilitates considerably the treatment of patients at all levels of health care, but particularly in primary care units, since the risks to the patient during intervention and the emergence of side effects are minimised.
Viable possibilities for improving ATL therapy
The essential attributes of drugs intended for treatment of NTDs are affordability, accessibility and efficacy with minimal side effects. With regard to antileishmanial agents, it is recognised that the search for alternative therapies must take into account the mechanisms of host cell invasion since Leishmania is an intracellular parasitic protozoan that infects mononuclear phagocytes. When Leishmania promastigotes are released into the skin through the bite of a sandfly, they avoid destruction by the host immune system by sheltering in different types of cells, especially dermal macrophages, fibroblasts, keratinocytes and dendritic cells. For this reason, antileishmanial drugs should exert their action at the cellular level by, for example inhibition of DNA/RNA synthesis, modification of enzyme activity or interaction with membrane receptors [42] .
Considerable efforts have been made towards the development of effective and safe antileishmanial agents in the last two decades, and a comprehensive review of the development of novel classes of natural and synthetic drugs is available [43] . In this article, we focus on two key strategies for improving ATL therapy in the short/ medium term, namely drug repositioning and nanotechnology.
Drug repositioning
The timelines for development, trialling, patenting and marketing of a new drug are lengthy and the whole process involves massive investment. Since NTDs affect mainly low-income people living in developing countries, the production of new antileishmanial drugs by pharmaceutical companies is not commercially viable unless some form of governmental assistance is forthcoming. A strategy involving the application of a known medication to an entirely different disease, socalled repositioning or repurposing, is appealing because the pharmacokinetics and safety characteristics of the drug will be known and some developmental steps can be bypassed [44] . This technique has important potential in Brazil where the ATL burden is increasing and spreading. In this context, it is interesting to note that the original indications for amphotericin B and pentamidine were as antifungal and general antimicrobial agents, respectively, but nowadays they are employed in ATL therapy in cases of antimonial failure. Moreover, the erythrocyte phosphodiesterase inhibitor pentoxifylline, currently recommended by the Brazilian Ministry of Health for use in combination with MA in the treatment of mucocutaneous ATL, was originally developed for use in peripheral vascular diseases. However, the repositioned drugs mentioned above tend to be somewhat expensive and, in the case of amphotericin B and pentamidine, they still require parenteral administration because of their poor absorption properties from the GI. Table 1 shows a selection of drugs that could be repositioned for use against L. (V.) braziliensis, ) panamensis, and is a valuable alternative for use in children who do not respond well to conventional treatment regimens [34, 45] . Unfortunately, miltefosine has never been affordable and available to the majority of ATL sufferers in high-burden countries owing to multiple changes in ownership rights over time and the failure to enforce the original agreement between WHO/TDR and Asta Medica guaranteeing the regular supply of the drug for public health use. To add to the list of setbacks associated with miltefosine, a lucrative privilege review voucher (PRV) awarded to the US license holder to stimulate the development of NTDs has, reportedly, produced no significant alteration in the affordability or availability of the drug [46] . However, miltefosine is no longer protected by patent and there is ample opportunity for the Brazilian government to encourage the production of a generic version of this drug.
Some of the potential agents listed in Table 1 are not effective on their own but could be used in combination therapies. For example a randomised double-blind clinical trial conducted in Peru by Miranda-Ver astegui et al. [56] showed that topical application of the antiviral imiquimod accelerated healing and reduced the amount of scarring when employed in combination with standard Table 1 Drugs of different classes that could be repositioned as antileishmanial agents against Leishmania (Viannia) braziliensis, Leishmania (Viannia) guyanensis, Leishmania (Viannia) panamensis and Leishmania (Leishmania) amazonensis antimonial therapy. Moreover, in a phase II randomised and controlled study, Machado et al. [52] established that oral administration of a low dose of the anticancer tamoxifen together with a standard antimonial regime improved 6-month cure rates in patients presenting localised ATL lesions from 40% with the standard therapy alone to 58% with the combined treatment. Although the results obtained in the small-scale trial were not statistically significant, the authors point out that the toxicity of tamoxifen is very low and dosage levels could be increased without serious side effects. It is likely that some type of combined therapy will be necessary for the effective treatment of the recalcitrant disseminated/diffuse and mucocutaneous forms of ATL, since Leishmania metastasis is apparently associated with the presence of endosymbiotic LRV1, which acts as a pathogenicity factor. Castiglioni et al. [59] have demonstrated that immunisation with LRV1 viral capsid polypeptide afforded protection against increased lesion severity in mice infected with L. (V.) guyanensis bearing LRV1. Furthermore, Kuhlmann et al. [60] have recently reported that two non-toxic adenosine analogues selectively inhibit LRV1, and could represent promising leads for drugs that reduce the severity of LRV1-bearing Leishmania infections.
Nanotechnology
Nanotechnology is the latest approach for drug delivery and has been primarily investigated for the chemotherapy of cancer and systemic fungal infections with the aim of delivering the drugs to targeted sites with minimum side effects. Nanocarriers are particles smaller than 1000 nm that have the ability to improve the pharmacokinetics and biodistribution of a therapeutic agent, decreasing its toxicity, improving its solubility and stability, and controlling its release at specific sites. The physicochemical properties of nanocarriers can be adjusted by changing their compositions, sizes, shapes and surface properties [61] .
Nanotechnology can be applied to the delivery of antileishmanial agents to macrophage-rich organs taking advantage of the phagocytic ability of these cells. Nanoparticles containing the drug are engulfed by the macrophages and the drug is released inside the phagolysosomes containing Leishmania amastigotes, thus improving the efficacy of the drugs and reducing side effects. The use of liposomal amphotericin B (AmBisomeâ; United Medical, São Paulo, SP, Brazil) as a second-line treatment for ATL represents one of the first examples of the efficient application of an organic nanocarrier. Although the product is available in Brazil, it suffers from two important disadvantages in that it must be applied exclusively by the IV route in a hospital setting and the complete treatment is too expensive for the majority of patients [62] .
Various studies relating to the use of nanoparticles for the delivery of MA via the oral route have been published [13] . For example Demicheli et al. [63] showed that a 1:1 complex of the antimonial with beta cyclodextrin administered orally to BALB/c mice infected with L. (L.) amazonensis was as effective as parenteral administration of MA at a two-fold higher dosage. However, the low water solubility of this complex limited its application in dogs and humans. With the aim of improving the oral bioavailability of Sb(V), Fernandes et al. [64] synthesised amphiphilic complexes of Sb(V) with alkylmethylglucamides and demonstrated that oral administration of a 1:3 complex of Sb(V) with n-octanoyl-Nmethylglucamide (SbL8) was highly effective in the suppression of Leishmania (Leishmania) infantum in a murine model. The oral bioavailability of the complex could be further improved using a formulation of SbL8 in water:propylene glycol (1:1) [65] . When given as repeated doses to BALB/c mice infected with L. (L.) amazonensis, the novel formulation significantly reduced the lesion parasite burden compared with SbL8 in water or the conventional antimonial drug administered by the parenteral route. The kinetic stability of SbL8 complexes in aqueous solution represents a unique property that may be explored in the future using them as carriers of other lipophilic drugs such as miltefosine or amphotericin B.
The antileishmanial activity of Sb(V) nanoparticles has also been studied by Franco et al. [66] who tested formulations of Sb(V) nanohybrid hydrosols in Syrian hamsters with lesions experimentally induced by L. (L.) amazonensis. Intralesional treatment with the hydrosols reduced the lesions more effectively (up to 1.85-times) than MA solution. The researchers reported that nanoparticles containing low doses of Sb penetrated directly into the cells, increasing the local concentration of the drug, a factor that is important in preventing parasite resistance and drug toxicity.
Employing an alternative strategy, Abamor et al. [67] used TiO 2 Ag-MA nanoparticles to deliver Sb(V) to promastigote and amastigote-macrophage cultures and to BALB/C mice with cutaneous leishmaniasis. The nanoparticles were more effective than MA alone against both parasite forms of Leishmania (Leishmania) tropica and reduced their metabolic activities up to 20-times. The nanoparticle formulations induced programmed cell death, stimulated the production of nitric oxide by macrophages and successfully healed cutaneous lesions.
Research into nanoparticle technology for the targeted delivery of MA or other agents that are active against cutaneous leishmaniasis is still in its infancy, but some significant progress has been made in recent years as described above (Figure 3) . However, regardless of potential therapeutic advantages, the technologies involved in the design and development of nanomedicines, as well as their pre-clinical and clinical evaluation, are generally more complex than those associated with conventional formulations. Thus, clinical translation of nanomedicines depends on overcoming many obstacles including reduction in design complexity, evaluation of effects in appropriate animal models of human disease, comprehension of the interactions between nanoparticles, tissues and cells, evaluation of large-scale manufacturing issues such as reproducibility, quality control, infrastructure, expertise and cost, and assessment of the biocompatibility and safety issues. Moreover, a number of difficulties relate to the granting of intellectual property, since there is no universal nomenclature for nanoparticles/nanostructures to prevent the issuing of multiple patents on the same nanostructure, and to establishing governmental regulatory protocols to ensure standardisation of manufacturing, characterisation and safety [68] .
Based on the above, the answer to the third question is that the chances of developing, in the near future, an affordable, accessible and non-toxic drug for ATL, or a new mode of delivery for MA other than by injection, are rather low. This situation occurs not because of the lack of interest of academia or other organisations in NTDs in general, but because of the absence of governmental commitment in bringing together the private and public sectors to tackle the problem. It is necessary to implement a concerted policy encouraging potential producers to develop and market an antileishmanial drug by reducing the barriers for regulatory approval and securing stable supplies at affordable prices.
Conclusions
All the evidence suggests that ATL therapy will continue to rely on systemic MA in the foreseeable future. Since this drug is relatively effective, perhaps the main research effort should be placed on new delivery methods aiming to reduce side effects, improve treatment adherence and optimise cost-effectiveness. In this context, alternative forms of delivery of this drug could be on the horizon and nanotechnology might very well provide the solution. However, in order to improve the chances of a formulation to be clinically translated, researchers need to focus on simplifying nanoparticle design and synthesis, bearing in mind the dosage for human use. Alternatively, the production of a bioequivalent of miltefosine would appear to be a more immediate solution since this drug is effective by oral administration and is no longer protected by patent, although such a route would require partnership among the various public and private stakeholders. 
